4198.TWO S&S Healthcare Holding Ltd.
- Market cap
- TWD 1.08B
- P/E
- -
- P/B
- 5.36x
- ROE
- -18.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4198.TWO undervalued?
Graham numberThe Graham number of S&S Healthcare Holding Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
S&S Healthcare Holding Ltd. fundamental analysis
No fundamental analysis for S&S Healthcare Holding Ltd. yet.
S&S Healthcare Holding Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About S&S Healthcare Holding Ltd.
S&S Healthcare Holding Ltd. focuses on the research and development, manufacture, and sales of medical imaging devices in Taiwan, the United States, Switzerland, and internationally. It develops digital diagnostic X-ray systems; and researches, develops, and produces bone densitometry and body composition assessment products. The company was formerly known as Swissray Global Healthcare Holding Ltd. and changed its name to S&S Healthcare Holding Ltd. in August 2020. S&S Healt…
Full company profileS&S Healthcare Holding Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
S&S Healthcare Holding Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 182M | 101M | 122M | 254M | 255M | 240M | 204M | 146M |
| Gross Profit | 14.6M | -23.4M | -7.93M | 38.4M | 35.7M | 75.0M | 67.1M | 51.5M |
| Operating Income | -131M | -133M | -104M | -96.9M | -91.4M | -68.4M | -47.2M | -49.2M |
| EBITDA | -124M | -93.5M | -71.6M | -33.6M | 134M | -17.6M | -27.9M | -16.0M |
| Net Income | -152M | -115M | -95.4M | -66.9M | 104M | -41.3M | -47.3M | -37.7M |
| EPS | -18 | -8.76 | -5.92 | -3.03 | 4.30 | -1.71 | -1.96 | -1.56 |
| Balance Sheet | ||||||||
| Total Assets | 298M | 288M | 294M | 531M | 613M | 434M | 377M | 354M |
| Total Liabilities | 198M | 220M | 200M | 316M | 209M | 116M | 100M | 102M |
| Shareholders' Equity | 100.0M | 67.8M | 55.0M | 135M | 301M | 261M | 226M | 204M |
| Cash & Short-term Investments | 48.7M | 94.7M | 122M | 112M | 199M | 150M | 107M | 73.5M |
| Total Debt | - | 140M | 124M | 184M | 88.1M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -89.4M | -58.6M | -70.5M | -72.9M | -68.1M | -41.9M | -26.7M | -52.8M |
| Capital Expenditure | 790K | 9.75M | 9.84M | 69.2M | 31.1M | 19.1M | 3.52M | 4.89M |
| Free Cash Flow | -90.2M | -68.4M | -80.4M | -142M | -99.2M | -61.0M | -30.2M | -57.7M |
| Ratios | ||||||||
| ROE | -152.4% | -169.4% | -173.5% | -49.5% | 34.5% | -15.8% | -20.9% | -18.5% |
| ROA | -51.1% | -39.9% | -32.4% | -12.6% | 16.9% | -9.5% | -12.5% | -10.6% |
| Net Profit Margin | -83.9% | -113.3% | -78.0% | -26.3% | 40.7% | -17.2% | -23.2% | -25.9% |
| Debt to Equity | - | 2.06x | 2.26x | 1.36x | 0.29x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
S&S Healthcare Holding Ltd. dividends
S&S Healthcare Holding Ltd. has not paid dividends in the last 7 fiscal years.
Last stock split: 200:1000 on Aug 4, 2022.
Who owns S&S Healthcare Holding Ltd.
- Insiders 86.32%
- Institutions 0.00%
- Public & others 13.68%
- Shares outstanding 24.1M
- Free float 4.23M
S&S Healthcare Holding Ltd. company profile
- Company name
- S&S Healthcare Holding Ltd.
- Ticker
- 4198.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 85 Xinhu 1st Road, Taipei, Taiwan, 114
- Phone
- 886 2 8792 2671
- Website
- swissray.com
About S&S Healthcare Holding Ltd.
S&S Healthcare Holding Ltd. focuses on the research and development, manufacture, and sales of medical imaging devices in Taiwan, the United States, Switzerland, and internationally. It develops digital diagnostic X-ray systems; and researches, develops, and produces bone densitometry and body composition assessment products. The company was formerly known as Swissray Global Healthcare Holding Ltd. and changed its name to S&S Healthcare Holding Ltd. in August 2020. S&S Healthcare Holding Ltd. was founded in 1988 and is headquartered in Taipei, Taiwan.
S&S Healthcare Holding Ltd. management
3- Mr. Tien-Ying LeeCOO & Director
- Guo-Dong LinManager
- Yuxiang HuangAccounting Supervisor